Related references
Note: Only part of the references are listed.The 4th International Symposium on Alzheimer's Disease and Related Disorders in the Middle East, October 26-28, 2007, Athens, Greece
Changiz Geula et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2010)
Serum transthyretin levels in Swedish TTR V30M carriers
Joel Buxbaum et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2010)
A cellular perspective on conformational disease: the role of genetic background and proteostasis networks
Tali Gidalevitz et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2010)
Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis
Efstathios Kastritis et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study
Donna E. Reece et al.
BLOOD (2009)
Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens
Julie A. Vrana et al.
BLOOD (2009)
Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis
Alan H. Bryce et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
A. Dispenzieri et al.
LEUKEMIA (2009)
Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability
Tilmann Bochtler et al.
BLOOD (2008)
Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone
D. Lebovic et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Long-term outcome-of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation
Vaishali Sanchorawala et al.
BLOOD (2007)
Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response
Morie A. Gertz et al.
HAEMATOLOGICA (2007)
Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone ± thalidomide for systemic light-chain amyloidosis:: results of a phase II trial
Adam D. Cohen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis
Arnaud Jaccard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis
Giovanni Palladini et al.
BLOOD (2007)
Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins
RL Comenzo et al.
BLOOD (2006)
Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
A Dispenzieri et al.
BLOOD (2006)
Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis
V Sanchorawala et al.
BONE MARROW TRANSPLANTATION (2005)
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
MA Gertz et al.
AMERICAN JOURNAL OF HEMATOLOGY (2005)
The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)
G Palladini et al.
BLOOD (2005)
Cardiovascular magnetic resonance in cardiac amyloidosis
AM Maceira et al.
CIRCULATION (2005)
Systemic AL amyloidosis due to non-Hodgkin's lymphoma: an unusual clinicopathologic association
AD Cohen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
A Dispenzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Molecular mechanisms of amyloidosis
G Merlini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy
HJ Lachmann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis
G Palladini et al.
CIRCULATION (2003)
Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis.
HJ Lachmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
